Kimberly R. Pechman1,2, Deborah L. Donohoe2,3, Devyani P. Bedekar2,3, Kathleen M. Schmaind2,4
1Neurosurgery, Medical College of Wisconsin, Millwaukee, WI, United States; 2Translational Brain Tumor Research Program, Medical College of Wisconsin, Milwaukee, WI, United States; 3Radiology, Medical College of Wisconsin, Milwaukee, WI, United States; 4Radiology & Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States
Few systematic studies have examined optimal timing for combining anti-angiogenic therapy with chemotherapy for brain tumor treatment. MRI measures of enhancing tumor volume have proven unreliable since decreases in enhancement may be independent of biologic effect. The purpose of this study was to use rCBV, derived from DSC-MRI, to optimize combination of anti-VEGF agent, B20, and chemotherapeutic, temozolomide, for treatment of U87 brain tumor models. The studies demonstrate optimal combination occurs when temozolomide is started two or four days after starting B20 treatment. Inhibition of tumor volume demonstrated different trends, which trend is more predictive of optimal response needs further exploration and validation.